Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Illumina ( (ILMN) ) just unveiled an update.
On November 25, 2025, Illumina, Inc. completed a public offering of $500 million in 4.750% notes due 2030. The company plans to use the proceeds for general corporate purposes, including repaying existing debt and potentially completing the acquisition of SomaLogic, Inc., which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (ILMN) stock is a Buy with a $195.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Outperform.
Illumina’s strong performance in the earnings call and bullish technical indicators are the most significant factors driving the score. Financial performance shows recovery but is tempered by increased leverage and cash flow challenges. Valuation is reasonable, supporting a positive outlook.
To see Spark’s full report on ILMN stock, click here.
More about Illumina
Illumina, Inc. operates in the biotechnology industry, focusing on the development and manufacturing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Average Trading Volume: 1,733,784
Technical Sentiment Signal: Buy
Current Market Cap: $19.25B
See more insights into ILMN stock on TipRanks’ Stock Analysis page.